Лечение Острого Психоза Вследствие Употребления Синтетических Каннабиноидов

Кекелидзе, З.И.; Klimenko, Taras; Козлов, А.А.; Шахова, С.М.

doi:10.26617/1810-3111-2017-3(96)-16-20

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Интерес исследователей к данным синтетическим ПАВ обусловлен не только их высокой наркогенностью, но и значительной частотой развития психотических расстройств на фоне их приема [5][6][7][8][9]. До настоящего времени оценка эффективности различных методов терапии психотических состояний, развившихся при употреблении современных синтетических ПАВ, не проводилась в контролируемых исследованиях, поэтому в реальной клинической практике лечебные мероприятия при данных психотических расстройствах осуществляются по аналогии с лечением алкогольных психозов, расстройств шизофренического спектра или же на основе рекомендаций токсикологов [4,5,[10][11][12][13][14][15][16]. Таким образом, существует насущная потребность в разработке научно обоснованных дифференцированных терапевтических алгоритмов купирования данных психотических состояний [6,8,12,17].…”

Section: Introductionunclassified

Treatment of Acute Drug-Induced Psychoses, Associated with Modern Synthetic Psychoactive Substances

et al. 2023

View full text Add to dashboard Cite

Use of new synthetic drugs (synthetic cannabinoids — “spices”, synthetic psychostimulants — “salts”, synthetic GABA-agonists — “butyrates”) is associated with a high risk of psychoses. Nowadays there are no evidence-based guidelines for treatment of these psychotic disorders. Objective: to develop effective therapeutic strategies for the treatment of acute substance-induced psychoses associated with modern synthetic drugs. Material and methods: 96 patients with substance-induced psychoses associated with synthetic cannabinoids (n = 32), synthetic psychostimulants (n = 33), and synthetic GABA-agonists (n = 31) were examined. In these groups we estimated effectiveness of different combination therapy: desintoxication and benzodiazepine, desintoxication and benzodiazepine and haloperidol, desintoxication, benzodiazepine and phenibut. The following methods were used: clinical-psychopathological, laboratory, statistics. Results: сomparative efficacy of therapeutic strategies differed in three investigated groups. In psychoses associated with synthetic cannabinoids the most effective strategy was haloperidol add-on. Differences between treatment approaches in group of psychostimulants-induced psychoses were not found. In psychoses associated with synthetic GABA-agonists the most effective strategy was phenibut add-on. Conclusion: the choice of effective therapeutic intervention in drug-induced psychosis should be based on type of synthetic drug.

show abstract

Section: Introductionunclassified

Treatment of Acute Drug-Induced Psychoses, Associated with Modern Synthetic Psychoactive Substances

et al. 2023

View full text Add to dashboard Cite

show abstract

Peculiarities of Clinical Symptoms, Somatic Complications, Approaches to Therapy and Outcomes of Delirium Induced by Exposure to Synthetic Cannabinoids: Systematic Review

Fedotov,

Volodin,

Novikov

et al. 2023

I.P. Pavlov Russian Medical Biological Herald

View full text Add to dashboard Cite

INTRODUCTION: The use of synthetic cannabinoids (SCs) is an urgent healthcare problem, due to, among other things, a high number of complications. AIM: To systematize the peculiarities of clinical presentation, somatic complications, effectiveness of empirical approaches to therapy, and probable outcomes of delirium induced by exposure to SCs. MATERIALS AND METHODS: The analysis of scientific publications selected by the keywords in eLibrary, СNKI, PubMed databases, was conducted. According to PRISMA recommendations, 20 articles were taken for analysis. RESULTS: Today, it is impossible to predict the period when SC-induced delirium may occur. It can start after one-time intake of even small dose, and can occur both due to intoxication and with the underlying withdrawal state on the 2nd4th days after the last use. Besides classic symptoms, the clinical picture of delirium is characterized by many symptoms of schizophrenic psychoses: hallucinations of threatening or drug-addicted content; secondary paranoid delusion, less expressed than hallucinations; aggressiveness and agitated behavior; some formal thinking disorders; rarely, KandinskiClerambault and oneiroid syndromes. There are reported cases of severe somatic complications in the form of depression of consciousness, rhabdomyolysis, acute renal failure, cardiomyopathy, myocardial infarction, epilepsy, infectious complications with the underlying weakened immunity. Therapy of SC-induced delirium includes detoxification and metabolic therapy, administration of antipsychotics and tranquilizers; use of resuscitation measures in case of depression of consciousness and development of life-threatening conditions. SC-induced delirium lasts from several hours to several days. In most cases, it terminates with complete recovery with amnesia of the period of confusion and asthenia, but in some cases fatal outcomes are reported caused not only by accidents such as road accidents or suicide, but also by somatic complications (most often of infectious character, or multi-organ failure). CONCLUSION: SСs remain relevant due to high frequency of their use and continuous emergence of new analogs to substances of this group. They have multidirectional effect, and so far it is difficult to predict at what period the delirium induced by them may occur.

show abstract

Лечение Острого Психоза Вследствие Употребления Синтетических Каннабиноидов

Cited by 2 publications

References 0 publications

Treatment of Acute Drug-Induced Psychoses, Associated with Modern Synthetic Psychoactive Substances

Treatment of Acute Drug-Induced Psychoses, Associated with Modern Synthetic Psychoactive Substances

Peculiarities of Clinical Symptoms, Somatic Complications, Approaches to Therapy and Outcomes of Delirium Induced by Exposure to Synthetic Cannabinoids: Systematic Review

Contact Info

Product

Resources

About